-  Obstetrics and Gynecology 
 -  Rehabilitation 
 -  Reproductive Medicine 
  
    Abstract
               
                  STUDY QUESTION
                  What clinical and laboratory differences emerge from parallel direct comparison of embryos reaching the blastocyst stage between Days 4, 5, 6, and 7 (Days 4–7)?
               
               
                  SUMMARY ANSWER
                  Increasing times to blastocyst formation are associated with a worse clinical outcome and perturbations in developmental patterns appear as early as the fertilization stage.
               
               
                  WHAT IS KNOWN ALREADY
                  Previous evidence indicates that later times to blastocyst development are associated with a worse clinical outcome. However, the vast majority of these data concern Day 5 and Day 6 blastocysts, while Day 4 and Day 7 blastocysts remain less thoroughly investigated. In addition, studies comparing in parallel the developmental patterns and trajectories of Day 4–7 blastocysts are lacking. This leaves unanswered the question of when and how differences among such embryos emerge. Acquisition of such knowledge would significantly contribute to understanding the relative impact of intrinsic and extrinsic causes of embryo developmental kinetics and competence.
               
               
                  STUDY DESIGN, SIZE, DURATION
                  This retrospective study involved time-lapse technology (TLT) monitoring of Day 4 (N = 70), Day 5 (N = 6147), Day 6 (N = 3243), and Day 7 (N = 149) blastocysts generated in 9450 ICSI cycles. Oocyte retrievals were carried out after clomiphene citrate-based minimal ovarian stimulation, between January 2020 and April 2021.
               
               
                  PARTICIPANTS/MATERIALS, SETTING, METHODS
                  Couples included in the study presented with different diagnoses, mainly male factor and unexplained infertility. Cases involving cryopreserved gametes or surgically retrieved sperm were excluded. Microinjected oocytes were assessed by a combined TLT-culture system. Day 4–7 blastocyst groups were compared in terms of morphokinetics (pronuclear dynamics, cleavage patterns and timings, and embryo quality) and clinical outcome. Clinically usable blastocysts were cryopreserved and transferred in single vitrified-warmed blastocyst transfers (SVBT).
               
               
                  MAIN RESULTS AND THE ROLE OF CHANCE
                  From 19 846 microinjected oocytes, 17 144 zygotes (86.4%) were obtained. Overall, the blastocyst development rate was 56.0%. Rates of blastocysts formation on Days 4, 5, 6, and 7 were 0.7%, 64.0%, 33.8%, and 1.6%, respectively. The average expanded blastocyst development times were 98.4 ± 0.4, 112.4 ± 0.1, 131.6 ± 0.1, and 151.2 ± 0.5 h in the Day 4–7 groups, respectively. Female age was positively associated with longer times to blastocyst development. Rates of both inner cell mass (ICM) and trophectoderm (TE) morphological grade A blastocysts were negatively associated with the day of blastocyst development (P < 0.0001). The differences in development times and intervals increased progressively until blastocyst expansion (P < 0.0001 for all development times). Strikingly, such differences were already markedly evident as early as the time of pronuclear fading (tPNf) (20.6 ± 0.3, 22.5 ± 0.0, 24.0 ± 0.0, 25.5 ± 0.3; Days 4–7, respectively; P < 0.0001). Rates of cleavage anomalies (tri-/multi-chotomous mitosis or rapid cleavage) occurring at the first or second/third division cycles were also positively associated with longer times to blastocyst development. Implantation, ongoing pregnancy, and live birth rates were progressively reduced with increasing blastocyst development times (P < 0.0001), even after stratification for maternal age. When controlled for female age, male age, number of previous embryo transfer cycles, morphological grade of the ICM and TE, and progesterone supplementation, the probabilities of implantation, clinical, and ongoing pregnancy and live birth were significantly decreased in Day 6 blastocysts in comparison to Day 5 blastocysts. Follow-up data on birth length, weight, and malformations were comparable among the four blastocyst groups.
               
               
                  LIMITATIONS, REASONS FOR CAUTION
                  The study is limited by its retrospective design. Having been obtained from a single centre, the data require independent validation.
               
               
                  WIDER IMPLICATIONS OF THE FINDINGS
                  This study extends previous data on the relation between time of blastocyst formation and clinical outcome. It also indicates that differences in developmental times and patterns of Day 4–7 blastocysts occur as early as the fertilization stage, possibly dictated by intrinsic gamete-derived factors.
               
               
                  STUDY FUNDING/COMPETING INTEREST(S)
                  This study was supported by the participating institutions. The authors have no conflict of interest to declare.
               
               
                  TRIAL REGISTRATION NUMBER
                  N/A.
               
  Need a simple solution for managing your BibTeX entries? Explore CiteDrive!
  - Web-based, modern reference management
  - Collaborate and share with fellow researchers
  - Integration with Overleaf
  - Comprehensive BibTeX/BibLaTeX support
  - Save articles and websites directly from your browser
  - Search for new articles from a database of tens of millions of references
  
 Try out CiteDrive    More from our Archive
  -   
  DOI: 10.1002/uog.26309  2023 
  Effect of intrapartum epidural analgesia on rate of emergency delivery for presumed fetal compromise: nationwide registry‐based cohort study 
  S. E. Damhuis, H. Groen, B. Thilaganathan, W. Ganzevoort, S. J. Gordijn 
    -   
  DOI: 10.1002/uog.26308  2023 
  Epidural analgesia and emergency delivery for presumed fetal compromise: <i>post‐hoc</i> analysis of <scp>RAVEL</scp> multicenter randomized controlled trial 
  E. S. E. Tabernée Heijtmeijer, H. Groen, S. E. Damhuis, L. M. Freeman, J. M. Middeldorp, W. Ganzevoort, S. J. Gordijn 
    -   
  DOI: 10.1111/mcn.13546  2023 
  A qualitative study of public health nurses' perspectives and experiences on nutritional guidance for parents of infants and toddlers 
  Christine Helle, Elisabet R. Hillesund, Nina Cecilie Øverby 
    -   
  DOI: 10.1002/uog.26303  2023 
  Screening for pre‐eclampsia by maternal serum glycosylated fibronectin at 11−13 weeks' gestation 
  N. Sokratous, M. Bednorz, P. Sarli, O. E. Morillo Montes, A. Syngelaki, A. Wright, K. H. Nicolaides 
    -   
  DOI: 10.1097/ogx.0000000000001159  2023 
  Cannabis and Pregnancy: A Review 
  Sarena Hayer, Ava D. Mandelbaum, Lester Watch, Kimberly S. Ryan, Madeline A. Hedges, Jennifer A. Manuzak, Charles A. Easley, Danny J. Schust, Jamie O. Lo 
    -   
  DOI: 10.1002/ijgo.14989  2023 
  Descriptive spectrum of thiamine deficiency in pregnancy: A potentially preventable condition 
  Sobia Nisar, Ozaifa Kareem, Umar Muzaffer, Masood Tanvir, Mohd. Ashraf Ganaie, Rabia Nazir Ahmed 
    -   
  DOI: 10.1111/aogs.14602  2023 
  Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative <scp>TPOAb</scp> and early child neurodevelopment: A prospective real‐world clinical trial 
  Zhekun Zhao, Qiongjie Zhou, Huanqiang Zhao, Yu Xiong, Xiaotian Li 
    -   
  DOI: 10.1111/jog.15743  2023 
  Development and internal validation of a multivariable prediction model for the quality of life of cervical cancer survivors 
  Jorge Cea García, Laura Ríos‐Pena, M. Carmen Rubio Rodríguez, Francisco Márquez Maraver, Inmaculada Rodríguez Jiménez 
    -   
  DOI: 10.1111/ajo.13719  2023 
  Intrahepatic cholestasis of pregnancy – Diagnosis and management: A consensus statement of the Society of Obstetric Medicine of Australia and New Zealand (<scp>SOMANZ</scp>): Executive summary 
  William M. Hague, Annette Briley, Leonie Callaway, Marloes Dekker Nitert, Jessica Gehlert, Dorothy Graham, Luke Grzeskowiak, Angela Makris, Corey Markus, Philippa Middleton, Michael J. Peek, Antonia Shand, Michael Stark, Jason Waugh 
    -   
  DOI: 10.1002/ijgo.14983  2023 
  Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (<scp>CIN</scp>) 2/3 
  Nerlyne Desravines, Chiu‐Hsieh Hsu, Sopan Mohnot, Vikrant Sahasrabuddhe, Margaret House, Edward Sauter, Siobhan O'Connor, Julie E. Bauman, H.‐H. Sherry Chow, Lisa Rahangdale